AMP945 as Effective as Ofev in IPF Mouse Model; Phase 2 Trial Planned
The experimental oral therapy AMP945, from Amplia Therapeutics, is as effective as the approved therapy Ofev (nintedanib) at reducing tissue scarring, or fibrosis, in a mouse model of idiopathic pulmonary fibrosis (IPF), the company said. In addition, findings from an already completed Phase 1 trial in healthy…